×
About 262 results

ALLMedicine™ Best Disease Center

Research & Reviews  131 results

Managing the front-line treatment for diffuse large B cell lymphoma and high-grade B ce...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7436686
British Journal of Haematology References; de la Cruz-Benito B, Lázaro-Del Campo P et. al.

Aug 7th, 2020 - The COVID-19 pandemic has dramatically challenged care for cancer patients, especially those with active treatment who represent a vulnerable population for SARS-CoV-2 infection. Aggressive lymphoid neoplasms, such as diffuse large B cell lymphoma...

Human iPSC Modeling Reveals Mutation-Specific Responses to Gene Therapy in a Genotypica...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7413860
American Journal of Human Genetics; Sinha D, Steyer B et. al.

Jul 24th, 2020 - Dominantly inherited disorders are not typically considered to be therapeutic candidates for gene augmentation. Here, we utilized induced pluripotent stem cell-derived retinal pigment epithelium (iPSC-RPE) to test the potential of gene augmentatio...

A Bayesian method to estimate variant-induced disease penetrance.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7347235
PLoS Genetics; Kroncke BM, Smith DK et. al.

Jun 22nd, 2020 - A major challenge emerging in genomic medicine is how to assess best disease risk from rare or novel variants found in disease-related genes. The expanding volume of data generated by very large phenotyping efforts coupled to DNA sequence data pre...

A novel mutation of BEST1 gene in Best disease.
https://doi.org/10.1177/1120672120920536
European Journal of Ophthalmology; Campa C, Parmeggiani F et. al.

Apr 23rd, 2020 - To describe a new genetic variation of BEST1 gene in Best vitelliform macular dystrophy. A patient with bilateral multiple retinal yellowish lesions at the posterior pole underwent fluorescein angiography, fundus autofluorescence, optical coherenc...

Sorafenib vs. Lenvatinib as First-line Therapy for Advanced Hepatocellular Carcinoma Wi...
https://doi.org/10.21873/anticanres.14193
Anticancer Research; Kuzuya T, Ishigami M et. al.

Apr 2nd, 2020 - We aimed to compare the outcomes between sorafenib and lenvatinib as first-line therapy for advanced hepatocellular carcinoma (HCC) with major portal vein tumor thrombosis (Vp3/4). This retrospective study enrolled 41 HCC patients with Vp3/4 and C...

see more →

Clinicaltrials.gov  131 results

Managing the front-line treatment for diffuse large B cell lymphoma and high-grade B ce...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7436686
British Journal of Haematology References; de la Cruz-Benito B, Lázaro-Del Campo P et. al.

Aug 7th, 2020 - The COVID-19 pandemic has dramatically challenged care for cancer patients, especially those with active treatment who represent a vulnerable population for SARS-CoV-2 infection. Aggressive lymphoid neoplasms, such as diffuse large B cell lymphoma...

Human iPSC Modeling Reveals Mutation-Specific Responses to Gene Therapy in a Genotypica...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7413860
American Journal of Human Genetics; Sinha D, Steyer B et. al.

Jul 24th, 2020 - Dominantly inherited disorders are not typically considered to be therapeutic candidates for gene augmentation. Here, we utilized induced pluripotent stem cell-derived retinal pigment epithelium (iPSC-RPE) to test the potential of gene augmentatio...

A Bayesian method to estimate variant-induced disease penetrance.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7347235
PLoS Genetics; Kroncke BM, Smith DK et. al.

Jun 22nd, 2020 - A major challenge emerging in genomic medicine is how to assess best disease risk from rare or novel variants found in disease-related genes. The expanding volume of data generated by very large phenotyping efforts coupled to DNA sequence data pre...

A novel mutation of BEST1 gene in Best disease.
https://doi.org/10.1177/1120672120920536
European Journal of Ophthalmology; Campa C, Parmeggiani F et. al.

Apr 23rd, 2020 - To describe a new genetic variation of BEST1 gene in Best vitelliform macular dystrophy. A patient with bilateral multiple retinal yellowish lesions at the posterior pole underwent fluorescein angiography, fundus autofluorescence, optical coherenc...

Sorafenib vs. Lenvatinib as First-line Therapy for Advanced Hepatocellular Carcinoma Wi...
https://doi.org/10.21873/anticanres.14193
Anticancer Research; Kuzuya T, Ishigami M et. al.

Apr 2nd, 2020 - We aimed to compare the outcomes between sorafenib and lenvatinib as first-line therapy for advanced hepatocellular carcinoma (HCC) with major portal vein tumor thrombosis (Vp3/4). This retrospective study enrolled 41 HCC patients with Vp3/4 and C...

see more →